Despite significant advances in treatment of primary tumors, metastatic cancer remains a leading cause of solid cancer mortality. HiberCell seeks to change that. As “the dormancy company,” we are the first company exclusively focused on therapeutically modulating the biology and mechanisms of tumor dormancy. Toward this goal we are developing first-in-class therapeutics that target dormant disseminated tumor cells (DTCs) from solid and liquid cancers. Our ultimate goal is to prevent or delay the recurrence of cancer.
Location: United States, New York
Employees: 51-200
Total raised: $128.15M
Founded date: 2019
Investors 1
| Date | Name | Website |
| 17.07.2021 | ARCH Ventu... | archventur... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 22.05.2021 | Series B | $67.4M | - |
| 11.02.2019 | Series A | $60.75M | - |
Mentions in press and media 10
| Date | Title | Description |
| 22.05.2021 | HiberCell Raises $67.4M in Series B Financing; Secures $30M Debt Facility from Hercules Capital | HiberCell, a NYC-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, completed a Series B financing round for gross proceeds of $67.4m. Concurrent to this financing, the company closed on... |
| 19.05.2021 | HiberCell Closes $67.4 Million Series B Financing and Secures $30 Million Debt Facility from Hercules Capital | Proceeds to advance pipeline of clinical product candidates focused on preventing cancer relapse and metastasis NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- HiberCell, a biotechnology company developing therapeutics focused on preventing canc... |
| 21.01.2021 | HiberCell Expands Scientific Advisory Board with Appointment of Lisa M. Coussens, Ph.D., and Ronald Wek, Ph.D. | |
| 02.12.2020 | HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer | |
| 07.02.2019 | Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence | The company’s pipeline page lists two potential product candidates, HC-5404 and HC-5407, in preclinical discovery for solid tumor metastasis and also recurrences of solid and liquid tumors. The company was founded based on research conducte... |
| 07.02.2019 | HiberCell Raises $60.75M in Series A Funding | HiberCell, a New York City-based biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, raised $60.75m in Series A funding. The round was led by Arch Venture Partners, with participation from Hill... |
| 07.02.2019 | HiberCell Closes $60.75 Series A | HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series A funding led by ARCH Venture Partners. HiberCell is the first company exclusively focused... |
| 07.02.2019 | HiberCell Closes $60.75 Series A | HiberCell, a biotechnology company developing therapeutics focused on preventing cancer relapse and metastasis, launched today with $60.75M in Series A funding led by ARCH Venture Partners. HiberCell is the first company exclusively focused... |
| 07.02.2019 | HiberCell Launches With $60.75M | NEW YORK, NY, HiberCell launched today with $60.75M in Series A funding >> Click here for more funding data on HiberCell >> To export HiberCell funding data to PDF and Excel, click here HiberCell, a biotechnology company ... |
| - | Startup HiberCell gets more than $60M to focus on mechanism behind cancer metastasis, recurrence | Researchers at New York’s Mount Sinai Health System have launched a company grown out of research into the mechanisms behind cancer metastases. HiberCell, also based in New York, launched Thursday with a $60.75 million Series A funding roun... |